This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunachie, S. J. Articles by Hill, A. V. S. Search for Related Content PubMed PubMed Citation Articles by Dunachie, S. J. Articles by Hill, A. V. S.

A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge

Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom,¹ Malaria Program, Naval Medical Research Center, Silver Spring, Maryland,² Imperial College London, South Kensington, London, United Kingdom,³ Oxxon Therapeutics, Oxford, United Kingdom,⁴ Vical, Inc., San Diego, California⁵

Received 10 April 2006/ Accepted 17 July 2006

The safety, immunogenicity, and efficacy of DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP) or the circumsporozoite protein (CS) of Plasmodium falciparum. Sixteen healthy subjects who never had malaria (malaria-naive subjects) received two priming vaccinations with DNA, followed by one boosting immunization with MVA, with either ME-TRAP or CS as the antigen. Immunogenicity was assessed by ex vivo gamma interferon (IFN-) enzyme-linked immunospot assay (ELISPOT) and antibody assay. Two weeks after the final vaccination, the subjects underwent P. falciparum sporozoite challenge, with six unvaccinated controls. The vaccines were well tolerated and immunogenic, with the DDM-ME TRAP regimen producing stronger ex vivo IFN- ELISPOT responses than DDM-CS. One of eight subjects receiving the DDM-ME TRAP regimen was completely protected against malaria challenge, with this group as a whole showing significant delay to parasitemia compared to controls (P = 0.045). The peak ex vivo IFN- ELISPOT response in this group correlated strongly with the number of days to parasitemia (P = 0.033). No protection was observed in the DDM-CS group. Prime-boost vaccination with DNA and MVA encoding ME-TRAP but not CS resulted in partial protection against P. falciparum sporozoite challenge in the present study.

Editor: W. A. Petri, Jr.

This article has been cited by other articles:

• Bansal, A., Jackson, B., West, K., Wang, S., Lu, S., Kennedy, J. S., Goepfert, P. A. (2008). Multifunctional T-Cell Characteristics Induced by a Polyvalent DNA Prime/Protein Boost Human Immunodeficiency Virus Type 1 Vaccine Regimen Given to Healthy Adults Are Dependent on the Route and Dose of Administration. J. Virol. 82: 6458-6469 [Abstract] [Full Text]  
• Sanderson, F., Andrews, L., Douglas, A. D., Hunt-Cooke, A., Bejon, P., Hill, A. V. S. (2008). Blood-stage Challenge for Malaria Vaccine Efficacy Trials: A Pilot Study with Discussion of Safety and Potential Value. Am J Trop Med Hyg 78: 878-883 [Abstract] [Full Text]  
• Huaman, M. C., Martin, L. B., Malkin, E., Narum, D. L., Miller, L. H., Mahanty, S., Long, C. A. (2008). Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment of Plasmodium falciparum Merozoite Surface Protein-1 in Vaccinated Volunteers. J. Immunol. 180: 1451-1461 [Abstract] [Full Text]  
• IMOUKHUEDE, E. B., ANDREWS, L., MILLIGAN, P., BERTHOUD, T., BOJANG, K., NWAKANMA, D., ISMAILI, J., BUCKEE, C., NJIE, F., KEITA, S., SOWE, M., LANG, T., GILBERT, S. C., GREENWOOD, B. M., HILL, A. V. S. (2007). LOW-LEVEL MALARIA INFECTIONS DETECTED BY A SENSITIVE POLYMERASE CHAIN REACTION ASSAY AND USE OF THIS TECHNIQUE IN THE EVALUATION OF MALARIA VACCINES IN AN ENDEMIC AREA. Am J Trop Med Hyg 76: 486-493 [Abstract] [Full Text]